Author

M. Parikh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Assay:spatial transcriptomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Mehta· 2 shared G. M. Boland· 2 shared K. Yizhak· 2 shared M. Sade-Feldman· 2 shared N. Hacohen· 2 shared A. L. Gonye· 1 shared A. L. Tang· 1 shared A. Schneider· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Mehta

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response

J. H. Chen, L. T. Nieman, M. Spurrell, V. Jorgji, P. M. Richieri, K. H. Xu, R. Madhu, M. Parikh, I. Zamora, A. Mehta, C. S. Nabel, S. S. Freeman, J. D. Pirl, C. Lu, C. B. Meador, , N. Hacohen

The paper identifies immune hubs in lung cancer that are associated with better responses to PD-1-blockade immunotherapy and contain stem-like CD8 T cells.

bioRxiv · Apr 4, 2023Immunology

Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade

A. Mehta, M. Rucevic, E. Sprecher, M. Parikh, J. Chem, D. T. Frederick, E. Woods, L. Bi, D. Lieb, L. Hultin-Rosenberg, J. Guess, R. J. Park, A. Schneider, W. Michaud, B. Miao, , G. M. Boland

The paper identifies plasma proteomic biomarkers that predict non-response to PD1 blockade in melanoma patients and links them to tumor microenvironment biology.

bioRxiv · Feb 2, 2022 · PreprintCancer Biology